CD19 and neoplasm: Apart from acute toxicities including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) (5, 6), infection risk should not be neglected, which leads to the “on target, off-tumor” depletion of normal CD19-expressing B cells and malignancy prior to treatment and lymphodepletion chemotherapy (3, 7, 8).